Fig. 2
From: Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
Suppression of the viral propagation in cells with the FIT-039. A The KSHV viral loads were determined by the TaqMan PCR for RTA in culture media supernatants of the BCBL-1 cells. The KSHV copy number was determined from Ct values at 96 h after lytic induction with 0, 5, or 10 μM FIT-039 treatment. Data are shown for n = 9 for each condition. B The relative cell number of BCBL-1 (PEL, KSHV+), Raji (Burkitt lymphoma, KSHV−), B95-8 (monkey lymphocytes, KSHV−), and HaCaT (human keratinocytes KSHV−), determined with the WST-8 assay at 48 h after the 0 or 10 µM FIT-039 treatment are indicated. Data from three replicates are indicated for each condition. Mean ± SE are shown in (A) and mean ± SD in (B). 0.1% DMSO served as 0 µM control in (A) and (B). *, p < 0.05; ***, p < 0.001; n.s., p ≥ 0.05 by one-way ANOVA with Turkey’s multiple comparisons test in (A) and (B)